Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.10) per share. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.
Capital One Initiates Coverage On TXO Energy Partners with Overweight Rating, Announces Price Target of $35
Capital One analyst Phillips Johnston initiates coverage on TXO Energy Partners (NYSE:TXO) with a Overweight rating and announces Price Target of $35.
